Posted: 01/11/2023
The corporate team at Penningtons Manches Cooper has advised Imperial University spin-out, SPARTA Biodiscovery, on its partnership and up to £3.5 million funding from international life sciences group, Sartorius.
SPARTA Biodiscovery was created to bring novel analytical methods to the development and production of nanoparticles used in advanced medicines. After spinning out in 2022, the company has now secured investment from Sartorius that will support the deployment of its system in a range of commercial settings.
The company’s SPARTA® (single particle automated Raman trapping analysis) platform can provide detailed physico-chemical analysis of nanoparticles at high throughput on a single-particle basis. The platform will help accelerate the design of nanoparticles before they progress to clinical trials and play a key role in manufacturing and quality control, helping drug developers significantly shorten the time it takes to get innovative medicines to patients.
Headquartered in Göttingen, Germany, the Sartorius Group provides innovative laboratory instruments and consumables for life sciences research and use in the biopharmaceutical industry, along with bioprocessing solutions for the manufacture of biotech medicines and vaccines.
The Penningtons Manches Cooper team advising SPARTA (who also advised SPARTA on its initial spin-out) was led by corporate partner James Went, with support from associate Leo Shrimpton. Life sciences partner Chris Shelley and associate Mary-Clare Palmer also advised.
James Went, partner at Penningtons Manches Cooper, commented: “We are very pleased to have supported SPARTA since its initial spin-out and on this significant partnership with a leading industry player in Sartorius, and we look forward to seeing the team continue to grow the business with this support.”
Dr Jelle Penders, CEO and co-founder of SPARTA Biodiscovery, commented: “We are thrilled to have in Sartorius a partner with extensive experience in this space. The investment and support Sartorius will provide will allow us to move the analytical technology we’ve developed and proven over the past years onto the market quickly, together with consumables and bespoke software. James Went and the rest of the team at Penningtons Manches Cooper also deserve a special thanks for their hard work, insights and advice on this transaction.”
© 2024 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear
Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority under number 419867.
Return to news headlines 
